What is Azitra?
Azitra, Inc. is a clinical-stage biopharmaceutical firm headquartered in Branford, Connecticut, established in 2014. The company specializes in precision dermatology, developing novel therapies for diverse skin conditions. Azitra employs advanced scientific methodologies, including genetic engineering, proteomics, and microbiome research, to create targeted treatments. Its proprietary platform integrates a substantial microbial library with AI and machine learning to identify and advance therapeutic candidates. The company's pipeline targets conditions such as Netherton syndrome, EGFR inhibitor-associated rash, and ichthyosis vulgaris, with a strategic focus on engineered proteins and live biotherapeutic products, particularly genetically modified Staphylococcus epidermidis strains, to restore skin function.
How much funding has Azitra raised?
Azitra has raised a total of $33.3M across 4 funding rounds:
Debt
$2.1M
Series A
$14M
Debt
$150K
Series B
$17M
Debt (2018): $2.2M with participation from Connecticut Innovations and Bios Partners
Series A (2019): $14M led by KdT Ventures, Bios Partners, Godfrey Capital, and Connecticut Innovations
Debt (2020): $150K supported by PPP
Series B (2020): $17M featuring Connecticut Innovations, Bios Partners, and Leaps by Bayer
Key Investors in Azitra
Connecticut Innovations
Connecticut Innovations (ctinnovations.com) is Connecticuts strategic venture capital arm and quasipublic investment agency, providing equity and debt financing, strategic guidance, and connections to help innovative, growing companies in the state scale, with dedicated funds for sectors like AI/quantum, climate tech, and biosciences.
Bios Partners
Bios Partners is a venture capital firm focused on identifying and bringing advanced biotech innovations to market in the U.S. They aim to disrupt geographic favoritism in venture capital by investing in compelling scientific opportunities across the Central U.S. that are often overlooked.
KdT Ventures
KdT Ventures is a venture capital firm specializing in early-stage frontier science investing, focusing on transformative technologies in medicine, chemicals, and materials. They often provide the first institutional check into companies, leading or co-leading pre-seed and seed funding rounds.
What's next for Azitra?
With the recent strategic investment, Azitra is poised to advance its clinical development programs and further leverage its proprietary platform. The company's focus on the skin microbiome and engineered bacterial strains positions it to address significant unmet needs in dermatology. Future strategic initiatives will likely involve expanding its clinical trial pipeline, forging new collaborations, and potentially scaling manufacturing capabilities to support the progression of its therapeutic candidates through regulatory pathways. This latest financing round provides Azitra with the necessary resources to pursue its mission of delivering highly targeted and personalized dermatological treatments.
See full Azitra company page
